"Protein M Analogs And Fusion Proteins And Their Use For Inhibiting Antibody Function" in Patent Application Approval Process (USPTO 20240309055).

A patent application has been filed for a protein-based method that can block neutralizing antibodies (NAbs) and improve gene therapy delivery. The method involves using a protein called Mycoplasma protein M to prevent NAbs from neutralizing the therapeutic gene delivery agent, adeno-associated virus (AAV). This approach has shown promise in laboratory and animal studies and could potentially overcome the challenge of pre-existing NAbs in patients. The protein M method may also have applications in treating autoimmune disorders and disorders associated with excess antibodies. The patent application provides detailed information on the modified protein and its mutations, as well as fusion proteins and vectors encoding the protein. This information may be useful for researchers in the fields of biotechnology, immunology, and gene therapy. [Extracted from the article]